# Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

> **NCT05127122** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Direct Biologics, LLC**

## Conditions studied

- ARDS, Human

## Interventions

- **DRUG:** Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT05127122
- **Lead sponsor:** Direct Biologics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in development plan
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127122, "Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05127122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*